Kenneth A. Clark

CIK: 0001561736

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SMMT

Summit Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

SMMT
Summit Therapeutics Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
35K shares-
SMMT
Summit Therapeutics Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
17.8K shares at avg. $8.76-
SMMT
Summit Therapeutics Inc.
Jan 2, 2025
Award(A)
Stock Option (right to buy)
Direct
35K shares-
SMMT
Summit Therapeutics Inc.
Jan 2, 2025
Award(A)
Stock Option (right to buy)
Direct
17K shares at avg. $9.18-
SMMT
Summit Therapeutics Inc.
Oct 11, 2024
Award(A)
Stock Option (right to buy)
Direct
200K shares-

		Type	Shares	Price		Ownership
Jan 2, 2026	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	35,000	-	-	Direct
Jan 2, 2026	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	17,796	$8.76	-	Direct
Jan 2, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	35,000	-	-	Direct
Jan 2, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	16,991	$9.18	-	Direct
Oct 11, 2024	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	200,000	-	-	Direct

1-5 of 5 transactions

About Clark Kenneth A

Clark Kenneth A (SEC CIK 0001561736) files insider reports with the SEC as Director of Summit Therapeutics Inc. (SMMT).

Signal8 holds 3 ownership filings by Clark Kenneth A, all Form 4s, filed between Oct 15, 2024 and Jan 6, 2026. Those filings report 5 transactions, from Oct 11, 2024 to Jan 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Clark Kenneth A's filings is in MIAMI, FL.

Recent filings by Clark Kenneth A

Jan 2, 2026: Grants or awards of SMMT derivative securities (2 lines, Form 4, code A).
Jan 2, 2025: Grants or awards of SMMT derivative securities (2 lines, Form 4, code A).
Oct 11, 2024: Grant or award of SMMT derivative securities (Form 4, code A).

Other insiders filing for Summit Therapeutics Inc. (SMMT)

Anand Bhaskar, Chief Accounting Officer
Zanganeh Mahkam, Co-Chief Executive Officer
DUGGAN ROBERT W, Co-Chief Executive Officer
Soni Manmeet Singh, COO and CFO
Booth Robert F., Director
Xia Yu, Director

How to read Form 4 transaction codes